tbuckley/cabot-search huggingface dataset:
The challenge of looking after people with dementia
Authors: M. Marshall
Journal: BMJ (2001)

Papers p 426 

Many people with dementia end up being looked after in nursing homes and long stay wards. A study in this week's BMJ shows that the quality of life for this very vulnerable section of our community may be unacceptable. Ballard et al found that none of 484 people with dementia living in nursing homes or hospital wards were experiencing what they refer to as a “fair standard of care” (p 426).1 This state of affairs raises a host of issues—about regulation, expectations, and staffing.

The authors draw attention to perhaps the main one, the fact that the current systems of quality control are inadequate. In the case of independent nursing homes these are the registration and inspection teams. There is no parallel for long stay hospital wards in the NHS except the Scottish and English Health Advisory Services. In all parts of the United Kingdom the systems for registering and inspecting nursing and residential homes are going through a major overhaul, with national bodies being established to monitor and improve standards against a nationally agreed set of criteria. The aim is to make the process more …
[245] HEPATIC VENOUS PRESSURE GRADIENT (HVPG) PREDICTS THE FIRST CLINICAL DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C (CHC)-RELATED CIRRHOSIS
Authors: D. Rincon, O. Lo lacono, A. Hernando, J. Gomez, M. Salcedo, M.V. Catalina, C. Sanz, G. Clemente, A. Matilla, O. Nunez, R. Banares
Journal: Journal of Hepatology (2007)
Progression of fibrosis in hepatitis C with and without schistosomiasis: Correlation with serum markers of fibrosis
Authors: Sanaa M. Kamal, Bradley Turner, Qi He, Jens Rasenack, Leonardo Bianchi, Ahmed Al Tawil, Ahmed Nooman, Mahmoud Massoud, Margaret James Koziel, Nezam H. Afdhal
Journal: Hepatology (2006)

Serial liver biopsies are the gold standard by which the progression of fibrosis is evaluated. This longitudinal cohort study assessed the different rates in the progression of fibrosis using serial liver biopsies and serum fibrosis markers YKL-40 and PIIINP and the cytokines, transforming growth factor beta (TGF-β) and tumor necrosis factor alpha (TNF−α). A 10-year cohort study was performed in patients with hepatitis C virus (HCV) alone or HCV and schistosomiasis. Patients were enrolled at the time of acute HCV infection and prospectively evaluated with two liver biopsies (at entry and end of follow-up), and true rates in the progression of fibrosis were calculated per year. Serum YKL-40, N-terminal propeptide of collagen III (PIIINP), TGF-β, and TNF-α were measured, as well as the expression of TGF-β, TNF-α, and YKL-40 mRNA in liver tissue. A significant increase in the progression rates of fibrosis occurred in the coinfected group (0.61 ± 0.13) compared with the HCV monoinfection group (0.1 ± 0.06; P < .001)). The progression of fibrosis rate/year had a direct linear correlation for YKL-40 (r = 0.892, P < .001) and for PIIINP (r = 0.577, P < .01). YKL-40 showed a linear correlation with TGF-β (r = 0.897, P < .001). Hepatic mRNA levels of YKL-40 and TGF-β correlated with the serum levels, confirming a hepatic source for the elevated serum levels. In conclusion, serial cytokine and fibrosis markers can accurately determine the rate at which fibrosis is progressing, identifying both those with rapid fibrosis and those with stable disease. (HEPATOLOGY 2006;43:771–779.)
Successful treatment of severe psoriatic arthritis with infliximab in an 11-year-old child suffering from linear psoriasis along lines of Blaschko
Authors: S. Rott, R.M. Küster, U. Mrowietz
Journal: British Journal of Dermatology (2007)

Journal Article Successful treatment of severe psoriatic arthritis with infliximab in an 11‐year‐old child suffering from linear psoriasis along lines of Blaschko Get access S. Rott, S. Rott Psoriasis Center at the Department of Dermatology, University of Kiel, Schittenhelmstr. 7, 24105 Kiel, Germany *Department of Paediatric Rheumatology, Rheumaklinik Bad Bramstedt, Bad Bramstedt, Germany E‐mail: srott@dermatology.uni‐kiel.de Search for other works by this author on: Oxford Academic Google Scholar R.M. Küster, R.M. Küster Psoriasis Center at the Department of Dermatology, University of Kiel, Schittenhelmstr. 7, 24105 Kiel, Germany *Department of Paediatric Rheumatology, Rheumaklinik Bad Bramstedt, Bad Bramstedt, Germany E‐mail: srott@dermatology.uni‐kiel.de Search for other works by this author on: Oxford Academic Google Scholar U. Mrowietz U. Mrowietz Psoriasis Center at the Department of Dermatology, University of Kiel, Schittenhelmstr. 7, 24105 Kiel, Germany *Department of Paediatric Rheumatology, Rheumaklinik Bad Bramstedt, Bad Bramstedt, Germany E‐mail: srott@dermatology.uni‐kiel.de Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 157, Issue 1, 1 July 2007, Pages 191–192, https://doi.org/10.1111/j.1365-2133.2007.07928.x Published: 01 July 2007
Efficacy of a Weight Management Program in Overweight Children
Authors: Paul C. Young
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Announcement
Authors: Barry M. Manuel
Journal: New England Journal of Medicine (1991)

The officers of the Massachusetts Medical Society are pleased to announce the appointment of Jerome P. Kassirer, M.D., as the next Editor-in-Chief of the New England Journal of Medicine, effective July 1, 1991. Dr. Kassirer is now Sara Murray Jordan Professor and Vice-Chairman of the Department of Medicine at Tufts University and Associate Physician-in-Chief at New England Medical Center, Boston.The officers are also pleased to announce that Arnold S. Relman, M.D., will become Editor-in-Chief Emeritus, effective July 1, 1991.
The influence of the antibacterial monomer 12-methacryloyloxydodecylpyridinium bromide on the proliferation, differentiation and mineralization of odontoblast-like cells
Authors: Mariko Nishida, Satoshi Imazato, Yusuke Takahashi, Shigeyuki Ebisu, Takuya Ishimoto, Takayoshi Nakano, Yoshiyuki Yasuda, Takashi Saito
Journal: Biomaterials (2009)
Restrictive Mitral Annuloplasty With or Without Surgical Ventricular Restoration in Ischemic Dilated Cardiomyopathy With Severe Mitral Regurgitation
Authors: Yasuhiro Shudo, Kazuhiro Taniguchi, Koji Takeda, Taichi Sakaguchi, Toshihiro Funatsu, Hajime Matsue, Shigeru Miyagawa, Haruhiko Kondoh, Satoshi Kainuma, Koji Kubo, Seiki Hamada, Hironori Izutani, Yoshiki Sawa
Journal: Circulation (2011)

Background— We assessed changes in left ventricular (LV) volume and function and in regional myocardial wall stress in noninfarcted segments after restrictive mitral annuloplasty (RMA) with or without surgical ventricular restoration (SVR). Methods and Results— Thirty-nine patients with ischemic cardiomyopathy (ejection fraction ≤0.35) and severe mitral regurgitation (≥3) were studied before and 2.8 months after surgery with cine-angiographic multidetector computed tomography (cine-MDCT). Eighteen underwent RMA alone (RMA group) and 21 underwent RMA and SVR (RMA+SVR group). In addition to measuring conventional parameters (LV end-diastolic volume index [LVEDVI], LV end-systolic volume index [LVESVI], and LV ejection fraction), we evaluated the regional circumferential end-systolic wall stress and mean circumferential fiber shortening in both the basal and mid-LV regions using 3-dimensional cine-MDCT images. LV end-diastolic and end-systolic volume indexes were significantly greater in the RMA+SVR group than in the RMA group preoperatively, but these values did not differ significantly postoperatively. LV end-diastolic and end-systolic volume indexes decreased significantly, by 21% and 27% after RMA and by 35% and 42% after RMA and SVR, and the percent reductions in LV end-diastolic and end-systolic volume indexes were significantly larger in the RMA+SVR group. Regional end-systolic wall stress decreased and circumferential fiber shortening increased significantly in the noninfarcted regions after RMA with or without SVR. Conclusions— RMA plus SVR showed a potentially greater reduction of LV end-diastolic and end-systolic volume indexes than RMA alone. In selected patients with more advanced LV remodeling, concomitant SVR may favorably affect the LV reverse-remodeling process induced by RMA.
'... and Could Be I'm Irwin, but to &amp;lt;5%'
Authors: Irwin I. Rosenfeld
Journal: JAMA (1985)

<h3>To the Editor.—</h3> I read with interest the editorial by Lester S. King, MD,<sup>1</sup>in the July 12 issue ofThe Journal. It has been my practice, when greeting a new patient, to introduce myself using my doctor title, but in the course of the initial evaluation, I routinely ask the patient (after initially addressing him by his last name), what he prefers to be called. I find that the vast majority of patients, at least 95%, prefer to be called by their first name and prefer to call me "Dr Rosenfeld." There are a small number of patients who prefer to be called by their last names and a small but significant number of patients who ask to address me by my first name, which I allow. I obviously have no objection to this, and whichever way we address each other is fine and acceptable to me. My
Abstract 2312: Using multidimensional real-time cell profiling approach to identify novel inhibitors of key targets and pathways involved in cancer maintenance and progression
Authors: Ning Ke, Xiaobo Wang, Xiao Xu, Yama Abassi
Journal: Cancer Research (2011)

Abstract A high throughput cell-based phenotypic screening method was developed using real time cell analysis system which is based on impedance sensor technology. Using compounds with known mechanisms, we had previously demonstrated small molecule compounds produce characteristic time-dependent cell response profiles (TCRP) which could be indicative of mechanism of action. The cellular-basis for the anti-mitotic TCRP has been extensively validated using both anti-mitotic compounds and siRNAs targeting mitotic machineries (e.g. Eg5, PLK1 &amp; Mad2). In this study, we used the TCRP approach to screen a 119,595 compound library for novel anti-cancer agents. The screening was performed at a final concentration of 17.8 µM using a human non small cell lung cancer line, H1993. The TCRP was monitored for 48 hours after compound treatment and the data generated was analyzed using in-house developed software to perform clustering analysis. For each screening set, a panel of compounds with known mechanisms of action were used as positive control and also served as reference for TCRP-based clustering to predict mechanisms of action. After multi-dose confirmation, 239 hits with IC50 values less than 8.9 µM were subjected to TCRP analysis. In comparison with reference TCRP patterns, we indentified 26 hits corresponding to tyrosine kinase inhibitors, 9 hits as DNA damaging agents, 125 hits as anti-mitotic agents, and 28 hits as cytostatic agents. Detailed characterization of 117 putative anti-mitotic compounds with traditional p-H3 based methods demonstrates 113 of them (96.6%) mediated mitotic arrest, thus demonstrating the robust predictive nature of the approach. We also have validated the putative tyrosine kinase inhibitors in in vitro kinase assays. TCRP-based phenotypic screening displays a novel drug screening approach with great potentials for discovering new pathway-modulating anticancer agents. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2312. doi:10.1158/1538-7445.AM2011-2312
Peer publishes bill to reinstate legal duty of health secretary to provide NHS
Authors: Z. Kmietowicz
Journal: BMJ (2013)

The independent peer David Owen is introducing a bill in the House of Lords to reinstate the secretary of state for health’s legal duty to provide and secure the NHS in England, which he says was abolished by the Health and Social Care Act last year.

A legal duty for the health secretary to ensure that health services were provided throughout the country has been in place since the NHS was established in 1948 and is the key underpinning of a health service that is free at the point of use, comprehensive, and democratically accountable, says a data briefing to support the bill.

But this changed under last year’s act and means that a range of bodies that were not accountable …
"INTRANASAL DISEASE IN THE PRODUCTION OF BRONCHIAL ASTHMA"
Authors: William Lintz
Journal: JAMA (1925)

<h3>To the Editor:</h3> —Intranasal operations for the cure of true bronchial asthma are still popular, and yet in my experience invariably futile. I feel that no apology is necessary for the following comment on the article entitled "Intranasal Disease in the Production of Bronchial Asthma" by M. J. Gottlieb, which appeared inThe Journal, July 11. After reading the article, one gets the erroneous impression that intranasal operations are of benefit in the relief of true bronchial asthma. If this were so, one would certainly have a right to expect results from intranasal operations in the "absorption cases," "where purulent disease is found (in the nose) and the symptoms are the result of absorption of protein material from the diseased area." As a matter of fact, the two cases cited under this heading yielded no results after intranasal treatments and operations. Results were obtained only after intravenous use of typhoid
Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy.
Authors: K. Blackwell, H. Burstein, G. Sledge, S. Stein, C. Ellis, M. Casey, J. Baselga, J. O'Shaughnessy
Journal: Cancer Research (2009)

Abstract Background: The synergistic interaction of lapatinib combined with trastuzumab was established in HER2-positive preclinical models, hence providing the rationale to evaluate this combination in a clinical setting. Progression-free survival (PFS) from study EGF104900 revealed the combination of lapatinib plus trastuzumab was superior to lapatinib alone in women with HER2-positive metastatic breast cancer (MBC) that progressed on multiple lines of trastuzumab-based therapy. Preliminary data showed a trend in overall survival (OS) favoring the combination therapy; however, data were not mature. Updated OS analyses are reported.Methods: Women with HER2-positive MBC progressing on prior trastuzumab-containing regimens were randomized to receive either lapatinib 1500 mg once daily or lapatinib 1000 mg once daily in combination with trastuzumab 2 mg/kg (after a 4-mg/kg loading dose). If objective disease progression occurred on or after 4 weeks of lapatinib alone, crossover to the combination arm was permitted. OS was summarized using Kaplan-Meier curves and compared between treatment arms using stratified log-rank tests. Analyses adjusting for baseline prognostic factors and crossover were also performed.Results: 296 women were randomized (148 per arm). The median number of prior trastuzumab-containing regimens for MBC treatment was 3. Of the women randomized to lapatinib alone, 52% (77/148) crossed over to the combination arm. At data cut-off for updated OS, 218 deaths (74%) had occurred. Median OS following treatment with lapatinib plus trastuzumab was 60.7 weeks compared with 41.4 weeks for lapatinib alone. A significant improvement in OS was demonstrated with combination therapy compared with lapatinib monotherapy (HR: 0.74; 95% CI: 0.57, 0.97; P=.026). The survival benefit was maintained after adjusting for baseline prognostic factors (HR: 0.71; 95% CI: 0.54, 0.93; P=.012). A trend toward a clinically relevant 25% reduction in risk of death (P=.080) was also observed after adjusting for crossover.Conclusion: A statistically significant OS benefit was observed in women with heavily pretreated, HER2-positive MBC treated with lapatinib in combination with trastuzumab compared with those treated with lapatinib alone. The actual survival benefit of the combination therapy may be underestimated due to the high frequency of crossover. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 61.
COLICINE K
Authors: Ronald D. Hinsdill, Walther F. Goebel
Journal: The Journal of Experimental Medicine (1966)

1. The transfer of type K. colicinogeny to Shigella sonnei Phase II has been described. 2. The colicine elaborated by this microorganism is a lipopolysaccharide-protein complex which resembles the somatic antigen of the noncolicinogenic parent. 3. Although the colicine K of Escherichia coli K235 and of Sh. sonnei differ both chemically and serologically, they resemble each other in that both elicit type K colicine-neutralizing antibodies and both have the same bactericidal specificity. 4. The nature of the chemical changes brought about in the somatic antigen of Sh. sonnei through the acquisition of colicinogeny remains unknown
Bechet vs Behçet: The Name Is Not the Same
Authors: Walter H. C. Burgdorf, David R. Bickers, Leonard J. Hoenig
Journal: JAMA Dermatology (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Scared to Death
Authors: M. M. Kulvin
Journal: JAMA (1966)

<h3>To the Editor:—</h3> The recent commentary inThe Journalon premonitions of death (<b>197</b>:516, 1966) brings to mind a similar episode, in which several of my colleagues have laughingly accused me of scaring a patient to death. Dr. Goodwin's comment that Dr. John M. T. Finney said "If a patient says, 'Doctor, if you operate on me, I am going to die'... don't operate on him" should be heeded very carefully, but I can go one step further. If the doctor feels he should not operate because of a patient's appearance, then let him postpone the operation. I was all set for a Caldwell-Luc procedure at the Veterans Hospital in Hines, Ill, when they wheeled the patient in. He was white as a sheet, with big globs of perspiration all over his face. He even said he was scared, but we knew that all he needed was reassurance. I
Audit of terminal care in a general practice.
Authors: A C Blyth
Journal: BMJ (1990)

To determine satisfaction of relatives and general practitioners with care of patients during terminal illness and make recommendations on improving terminal care in general practice.Interviews with available relatives of patients who had had terminal illnesses and died in 1987, supplemented by questionnaires; questionnaire survey of general practitioners after review of case notes of all their patients who had died of terminal illnesses in 1987.One urban general practice.34 Relatives of patients with terminal illnesses who died in 1987; five general practitioners from one practice.In six cases relatives were dissatisfied, mainly because of lack of communication; in eight cases doctors were dissatisfied because of communication, poor symptom control, and inadequate care.There is a need for improved communication between relatives and the health professionals involved in terminal care as well as better advice on services and benefits available to both patients and relatives. Bereavement counselling should be better organised.
An Assessment of the Exercise Capacity of Cardiac Patients
Authors: C. H. WYNDHAM, J. S. WARD
Journal: Circulation (1957)

An attempt is made to relate the level of exercise at which disability occurs in cardiac patients with known oxygen consumption figures for various tasks. The limit to the maximum level of exercise in some patients with rheumatic heart disease is set by circulatory parameters, as in normal subjects, in others it is set by the excessive ventilatory cost of exercise.
A recurrent splice-site mutation in the human hairless gene underlies congenital atrichia in Irish families
Authors: G.M. O'Regan, J. Zurada, A. Martinez-Mir, A.M. Christiano, A.D. Irvine
Journal: British Journal of Dermatology (2007)

Journal Article A recurrent splice‐site mutation in the human hairless gene underlies congenital atrichia in Irish families Get access G.M. O'Regan, G.M. O'Regan Department of Paediatric Dermatology, Our Lady's Hospital for Sick Children, Crumlin, Dublin 12, Ireland *Department of Dermatology, Columbia University, New York, NY, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar J. Zurada, J. Zurada Department of Paediatric Dermatology, Our Lady's Hospital for Sick Children, Crumlin, Dublin 12, Ireland *Department of Dermatology, Columbia University, New York, NY, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar A. Martinez‐Mir, A. Martinez‐Mir Department of Paediatric Dermatology, Our Lady's Hospital for Sick Children, Crumlin, Dublin 12, Ireland *Department of Dermatology, Columbia University, New York, NY, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar A.M. Christiano, A.M. Christiano Department of Paediatric Dermatology, Our Lady's Hospital for Sick Children, Crumlin, Dublin 12, Ireland *Department of Dermatology, Columbia University, New York, NY, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar A.D. Irvine A.D. Irvine Department of Paediatric Dermatology, Our Lady's Hospital for Sick Children, Crumlin, Dublin 12, Ireland *Department of Dermatology, Columbia University, New York, NY, U.S.A. Correspondence: Alan D. Irvine. E‐mail: alan.irvine@olhsc.ie Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 156, Issue 4, 1 April 2007, Pages 744–747, https://doi.org/10.1111/j.1365-2133.2006.07742.x Published: 01 April 2007